Press release
Fragment-Based Drug Discovery Market to Reach USD 3.2 Billion by 2035, Driven by Structural Biology Advancements and Expansion of Fragment Libraries | TMR
The global Fragment-based Drug Discovery (FBDD) Market is set for robust growth, projected to expand from US$ 1.1 billion in 2024 to US$ 3.2 billion by 2035, registering a strong CAGR of 10.6%, according to the latest market analysis. Increasing adoption of fragment-based techniques in drug design, the emergence of innovative fragment libraries, and expanding applications in oncology and central nervous system (CNS) disorders are key forces propelling the market forward.Discover essential conclusions and data from our Report in this sample -
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4741
FBDD Gains Momentum as Biopharma Refocuses on Novel Targets
As the biopharmaceutical sector faces mounting pressure to replenish pipelines amid rising incidences of oncology, immunology, and CNS diseases, fragment-based drug discovery has emerged as a preferred strategic approach. Unlike traditional high-throughput screening, FBDD utilizes low-molecular-weight chemical fragments that bind effectively to protein targets, even with weak affinities. This methodology enables the identification of novel chemical starting points, particularly in challenging targets such as protein-protein interactions and allosteric sites.
"Fragment-based drug discovery is redefining early-stage research by offering a more efficient route to first-in-class and best-in-class therapies," stated an industry analyst. "The combination of biophysical screening, computational chemistry, and advanced structural biology tools has made FBDD a cornerstone for innovative drug design."
Technological Innovations Accelerate Discovery and Validation
The widespread availability of high-field Nuclear Magnetic Resonance (NMR), X-Ray crystallography, and Cryo-Electron Microscopy (cryo-EM) has significantly improved hit confirmation, structure-based optimization, and binding analysis. These technologies are now routinely integrated into discovery workflows by both large pharmaceutical firms and specialized Contract Research Organizations (CROs).
Data integration platforms are also transforming decision-making in FBDD. Enterprise-level data lakes combining structure-activity relationship (SAR), biophysics, and pharmacology data are streamlining the design-make-test-analyze cycle. This convergence of disciplines accelerates lead optimization and improves ADME (Absorption, Distribution, Metabolism, and Excretion) profiling at earlier stages.
Fragment Libraries and AI Integration Fuel Market Expansion
A major driver of the global FBDD market is the evolution of fragment libraries. Modern libraries are increasingly diverse and structurally rich, incorporating scaffolds optimized for drug-likeness and chemical diversity. Specialized collections - such as covalent fragment libraries, RNA-targeted fragments, and AI-designed libraries - are expanding FBDD's reach into previously undruggable targets.
The integration of artificial intelligence and machine learning for virtual fragment screening is also reshaping the discovery process. Predictive modeling and physics-informed scoring approaches, including free-energy perturbation and water thermodynamics, are improving hit prioritization and fragment elaboration.
Biophysical Techniques Dominate the Technology Landscape
The biophysical techniques segment continues to lead the global FBDD market due to its superior sensitivity and reproducibility. Technologies such as NMR, Surface Plasmon Resonance (SPR), Isothermal Titration Calorimetry (ITC), and Mass Spectrometry provide detailed insights into fragment binding kinetics and thermodynamics. These methods remain essential in confirming fragment hits and guiding rapid optimization toward potent lead compounds.
Access our report for a comprehensive look at key insights -
https://www.transparencymarketresearch.com/fragment-based-drug-discovery-market.html
North America Leads Global Adoption
North America held the dominant share of the global FBDD market in 2024, supported by a concentration of advanced research infrastructure, pharmaceutical leaders, and biotechnology startups. The region benefits from substantial R&D funding, strong CRO networks, and a regulatory framework that encourages innovation in early drug discovery.
Prominent U.S. and Canadian research institutions continue to collaborate with CROs and technology vendors to accelerate FBDD workflows, further solidifying the region's leadership in fragment-based innovation.
Competitive Landscape and Strategic Collaborations
Leading market participants include Thermo Fisher Scientific Inc., Astex Pharmaceuticals, Domainex, Beactica Therapeutics AB, Charles River Laboratories, Evotec International GmbH, Sprint Bioscience, Structure Based Design Inc., Sygnature Discovery Ltd., Malvern Panalytical Ltd., Vernalis (R&D) Ltd. (HitGen Inc.), SARomics Biostructures, WuXi AppTec, Schrödinger, Inc., and ZOBIO BV.
The competitive landscape is characterized by platform-building strategies, multi-disciplinary partnerships, and digital integration. Companies are investing in cloud-native Electronic Laboratory Notebooks (ELNs) compliant with FAIR data standards (Findable, Accessible, Interoperable, and Reusable) to streamline research collaboration and enhance data traceability.
In April 2025, Enamine and Pohang Accelerator Laboratory (PAL) announced a strategic Memorandum of Understanding (MoU) aimed at accelerating fragment-to-lead transitions through combined chemical development and advanced screening technologies. This collaboration exemplifies a growing trend toward risk-sharing and option-to-license agreements in the FBDD space.
Buy this Premium Research Report to access comprehensive analysis -
https://www.transparencymarketresearch.com/checkout.php?rep_id=4741<ype=S
Future Outlook: FBDD as a Cornerstone for Mechanism-Driven Discovery
The future of fragment-based drug discovery is closely tied to the industry's shift toward mechanism-driven drug design and precision pharmacology. As therapeutic targets grow more complex, the flexibility of FBDD - coupled with next-generation screening tools and computational advancements - positions it as a sustainable and high-yield approach for pharmaceutical R&D.
Emerging frontiers in RNA-targeting fragments, molecular glues, and degrader discovery further highlight FBDD's potential to reshape modern drug pipelines. These advances are expected to reduce early-stage attrition rates, enhance target validation, and shorten time-to-market for innovative therapeutics.
Explore Latest Research Reports by Transparency Market Research:
Ophthalmic Optics & Instrument Market - https://www.transparencymarketresearch.com/ophthalmic-optics-instrument-market.html
Self-sampling Blood Collection & Storage Device Market - https://www.transparencymarketresearch.com/selfsampling-blood-collection-and-storage-device-market.html
Neurotrophic Keratitis Market - https://www.transparencymarketresearch.com/neurotrophic-keratitis-market.html
Sports Medicine Market - https://www.transparencymarketresearch.com/sports-medicine-market.html
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fragment-Based Drug Discovery Market to Reach USD 3.2 Billion by 2035, Driven by Structural Biology Advancements and Expansion of Fragment Libraries | TMR here
News-ID: 4264620 • Views: …
More Releases from Transparency Market Research
Electric Vehicle Battery Market to Soar to USD 566 Billion by 2035, Driven by Ra …
Electric Vehicle (EV) Battery Market-valued at US$ 74.6 billion in 2024-is projected to surge at a CAGR of 21.1% from 2025 to 2035, reaching a staggering US$ 566 billion by the end of the forecast period. This exponential growth reflects the accelerating global transition toward electric mobility, supported by aggressive sustainability goals, favorable government incentives, and technological advancements in battery systems.
Access key findings and insights from our Report in this…
Fermented Non-Dairy Non-Alcoholic Beverages Market to Reach USD 5,590 Mn by 2035 …
According to the latest industry analysis, the global fermented non-dairy non-alcoholic beverages market was valued at US$ 2,983.0 Mn in 2024 and is projected to reach US$ 5,590 Mn by 2035, expanding at a CAGR of 6.0% from 2025 to 2035. The market is witnessing rapid transformation as consumers shift toward plant-based, probiotic-rich, and clean-label functional drinks that support wellness, immunity, and digestive health.
The global beverage industry is undergoing a…
Harnessing the Sun for Sustainable Water: Solar Water Desalination Plant Market …
The global solar water desalination plant market is gaining momentum as countries around the world confront the growing challenges of freshwater scarcity, rising energy costs, and climate change. Valued at US$ 2.4 billion in 2024, the market is projected to grow at a CAGR of 7.3% from 2025 to 2035, reaching an estimated US$ 5.1 billion by 2035. As the demand for sustainable water production technologies intensifies, solar-powered desalination is…
Automotive Chassis System Market Set to Reach US$ 247.8 Bn by 2035 Amidst Innova …
The global automotive chassis system market is undergoing a remarkable transformation, driven by technological advancements, rising vehicle production, and the rapid electrification of the global automotive fleet. Valued at US$ 96.2 billion in 2024, the industry is projected to grow at a CAGR of 7.5% from 2025 to 2035, reaching approximately US$ 247.8 billion by 2035. As vehicles become smarter, lighter, and more efficient, the chassis system-the structural backbone of…
More Releases for FBDD
Oncology Small Molecule Drugs Market is Expected to Reach USD 167.6 Billion by 2 …
The global Oncology Small Molecule Drugs Market, valued at USD 89.2 billion in 2024, is projected to reach USD 167.6 billion by 2035, expanding at a robust CAGR of 5.9%. Driven by the rising prevalence of cancer, advancements in targeted therapies, and increasing demand for personalized medicine, this market is pivotal in transforming cancer treatment. This press release explores key growth drivers, projections, and opportunities for stakeholders in this dynamic…
Fragment-Based Drug Discovery Market Size, Share, Growth Forecast 2023-2032
The Fragment-Based Drug Discovery (FBDD) market has been gaining traction in recent years, emerging as a transformative approach in the pharmaceutical and biotechnology industries. The market size for FBDD was valued at USD 1.1 billion in 2022 and is projected to reach USD 3.8 billion by 2032, growing at a remarkable compound annual growth rate (CAGR) of 14.0% from 2023 to 2032. This article delves into the competitive landscape, future…
Fragment Based Drug Discovery Market Set to Reach USD 2.1 billion by 2031, Surgi …
The fragment-based drug discovery market encompasses a wide range of stakeholders, including pharmaceutical companies, contract research organizations (CROs), academic institutions, and technology providers. FBDD offers several advantages over traditional high-throughput screening approaches, including the ability to sample chemical space more comprehensively, target protein-protein interactions, and access novel binding sites that may be challenging to target with larger, more complex molecules. As a result, FBDD has gained traction in the pharmaceutical…
Global Fragment-Based Drug Discovery Market Outlook 2031
𝗚𝗹𝗼𝗯𝗮𝗹 𝗙𝗿𝗮𝗴𝗺𝗲𝗻𝘁-𝗕𝗮𝘀𝗲𝗱 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗠𝗮𝗿𝗸𝗲𝘁 𝗢𝘂𝘁𝗹𝗼𝗼𝗸 𝟮𝟬𝟯𝟭
The global fragment-based drug discovery (FBDD) market is poised for remarkable growth, with a projected compound annual growth rate (CAGR) of 11.5% from 2023 to 2031. This innovative approach to early-stage drug development has gained substantial attention due to its ability to revolutionize the way we discover and develop new therapeutic agents. In 2022, the FBDD market was valued at US$ 795.4 million, and…
Fragment-Based Drug Discovery Market Research Insight 2022| Industry Development …
InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Fragment-Based Drug Discovery Market by (technique (x-ray crystallography, nuclear magnetic resonance, surface plasmon resonance and other screening techniques), service (library screening, fragment screening and fragment optimization), End-users (hospitals, industry players and non-industry players) - Market Outlook and Industry Analysis 2030"
Get Demo Sample copy of Fragment-Based Drug Discovery Market Report at: https://www.insightaceanalytic.com/request-sample/1175
Over the…
Fragment-based Drug Discovery Market Key Trends & Industry Forecast 2015 - 2023
38.4% of the global fragment-based drug discovery market was collectively held by its top three players in 2014. Astex Pharmaceuticals, Charles River Laboratories International, Inc., and Sygnature Discovery were the key contributors to the market revenue at the time and are expected to retain their lead in the near future. A new research report released by Transparency Market Research states that with 52.3% of the global fragment-based drug discovery market…
